Response of carious enamel to TiF4 varnish treatment under diverse cariogenic activities in situ
Abstract
OBJECTIVE
To compare the effect of TiF4 and NaF varnishes on pre-demineralized bovine enamel under different cariogenic activities in situ.
METHODS
Twenty subjects participated of this in situ
study with 3 crossover phases (14 days each), in which they wore
palatal appliances containing demineralized bovine enamel samples (8
samples/appliance for phase) treated with TiF4, NaF (all with
2.45% F) or placebo varnish. The samples were subjected to different
cariogenic conditions (1. absence of biofilm accumulation and sucrose
exposure; 2. presence of biofilm and absence of sucrose exposure; 3.
presence of biofilm and 20% sucrose exposure 4x/day; 4. presence of
biofilm and 20% sucrose exposure 8x/day). All were exposed to fluoride
dentifrice (2x/day). The mineral content and lesion depth were evaluated
using transverse microradiography (TMR) and the data were subjected to
RM two-way ANOVA/Bonferroni tests (p<0 .05="" p="">
RESULTS
TiF4
varnish significantly increased the remineralization of artificial
carious lesions compared to placebo, regardless of the cariogenic
activity. On the other hand, the remineralizing effect of NaF varnish
was dependent on the cariogenic activity. For NaF, remineralization
happened only in conditions 1 and 3 compared to placebo varnish
(p < 0.0001). NaF was unable to prevent further demineralization
under biofilm accumulation and sucrose exposure 8x/day (condition 4). In
the absence of fluoride treatment, demineralization happened in all
conditions, except in the condition 1.
CONCLUSION
Therefore, 4% TiF4
varnish was the only treatment able to improve enamel remineralization
regardless of the cariogenic activity, while NaF varnish failed in
preventing further demineralization under high cariogenic activity in situ.
CLINICAL SIGNIFICANCE
4% TiF4
varnish showed better remineralizing effect compared to NaF varnish,
which was seen regardless of the cariogenic activity. This is a
promising finding to support the indication of TiF4 in the clinic.
0>
Comments